Minimal residual disease in EGFR-mutant non-small-cell lung cancer

Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual disease (MRD). This mini-review explores the mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bain, Nathan T., Wang, Yang, Arulananda, Surein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533094/
https://www.ncbi.nlm.nih.gov/pubmed/36212398
http://dx.doi.org/10.3389/fonc.2022.1002714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533094/
https://www.ncbi.nlm.nih.gov/pubmed/36212398
http://dx.doi.org/10.3389/fonc.2022.1002714

Ejemplares similares